Article Details
Retrieved on: 2025-02-13 18:01:24
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article explores biotechnology's role in developing alpha-synuclein inhibitors for treating neurodegenerative diseases like Parkinson's, Lewy body dementia, and multiple system atrophy. It highlights various therapeutic approaches and clinical trials aimed at reducing alpha-synuclein aggregation, a common neuropathological feature in these diseases.
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here